What types of MLTX share ownership did Kristian Reich report on this Form 4?

Kristian Reich reported both indirect and direct ownership of MoonLake (MLTX) Class A ordinary shares. Indirectly, through JeruCON Beratungsgesellschaft mbH, he reported 2,711,198 shares, and directly he reported holding 35,389 Class A ordinary shares.

MoonLake (MLTX) CSO Reich sells 1,100 shares via Rule 10b5-1 plan

Q: Were the MLTX insider transactions by Kristian Reich made under a Rule 10b5-1 plan?

Yes. The reported sale of 1,100 MLTX Class A ordinary shares by Kristian Reich was executed pursuant to a Rule 10b5-1 trading plan . The plan was adopted on March 10, 2026 , and governs the July 27, 2026 transaction.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, reported the sale of 1,100 Class A ordinary shares at $20.00 per share on July 27, 2026. The shares were owned by JeruCON Beratungsgesellschaft mbH and sold under a Rule 10b5-1 trading plan adopted March 10, 2026. After the transaction, Dr. Reich reported indirect beneficial ownership of 2,711,198 shares through JeruCON and direct ownership of 35,389 shares.

Insider Trade Summary 10b5-1

Net Seller: 1,100 shares

Net Sell 2 txns

Insider Reich Kristian

Role Chief Scientific Officer

Sold 1,100 shs ($22K)

Type	Security	Shares	Price	Value
Sale	Class A ordinary shares, par value $0.0001 per share ^{F1, F2}	1,100	$20.00	$22K
holding	Class A ordinary shares, par value $0.0001 per share	--	--	--

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 2,711,198 shares (Indirect, See footnote.); Class A ordinary shares, par value $0.0001 per share — 35,389 shares (Direct)

Footnotes (2)

F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
F2. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

Key Figures

Shares sold: 1,100 shares Sale price per share: $20.00 per share Indirect holdings after sale: 2,711,198 shares +2 more

5 metrics

Shares sold 1,100 shares Class A ordinary shares sold on July 27, 2026

Sale price per share $20.00 per share Price for 1,100 Class A ordinary shares sold July 27, 2026

Indirect holdings after sale 2,711,198 shares Indirectly owned Class A ordinary shares through JeruCON following the transaction

Direct holdings after sale 35,389 shares Directly owned Class A ordinary shares as of July 27, 2026

Transaction date July 27, 2026 Date of reported sale of Class A ordinary shares

Key Terms

Rule 10b5-1 trading plan, indirect beneficial owner, Section 16 of the Securities Exchange Act of 1934, Class A ordinary shares

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

indirect beneficial owner regulatory

"may be deemed ... to be the indirect beneficial owner of the ordinary shares"

Section 16 of the Securities Exchange Act of 1934 regulatory

"for purposes of Section 16 of the Securities Exchange Act of 1934"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

Class A ordinary shares financial

"Class A ordinary shares, par value $0.0001 per share"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/29/2026 - 04:11 PM Accepted by SEC EDGAR 07/29/2026 - 04:10 PM

FAQ

What insider transaction did MoonLake Immunotherapeutics (MLTX) report for Kristian Reich?

MoonLake Immunotherapeutics reported that Chief Scientific Officer Kristian Reich sold 1,100 Class A ordinary shares on July 27, 2026. The sale was reported at $20.00 per share and involved shares owned by JeruCON Beratungsgesellschaft mbH.

At what price and under what plan were MLTX shares sold by Kristian Reich?

The reported sale by Kristian Reich of MoonLake Immunotherapeutics (MLTX) was executed at $20.00 per share. According to the disclosure, this transaction occurred under a Rule 10b5-1 trading plan that was adopted on March 10, 2026.

How many MoonLake (MLTX) shares does Kristian Reich hold after the reported sale?

Following the July 27, 2026 transaction, Kristian Reich reported 2,711,198 MLTX Class A ordinary shares held indirectly through JeruCON Beratungsgesellschaft mbH and an additional 35,389 Class A ordinary shares held directly in his own name.

Were the MLTX insider transactions by Kristian Reich made under a Rule 10b5-1 plan?

Yes. The reported sale of 1,100 MLTX Class A ordinary shares by Kristian Reich was executed pursuant to a Rule 10b5-1 trading plan. The plan was adopted on March 10, 2026, and governs the July 27, 2026 transaction.

What is the relationship between Kristian Reich and JeruCON Beratungsgesellschaft mbH in the MLTX disclosure?

The ordinary shares involved in the MLTX transaction are owned by JeruCON Beratungsgesellschaft mbH. Kristian Reich may be deemed, for purposes of Section 16, to be the indirect beneficial owner of the shares owned by JeruCON, based on his ownership or position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reich Kristian

(Last)

(First)

(Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG

6300

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A ordinary shares, par value $0.0001 per share	07/27/2026		S⁽¹⁾		1,100	D	$20	2,711,198	I	See footnote.⁽²⁾
Class A ordinary shares, par value $0.0001 per share								35,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

2. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Kristian Reich	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR